Department of Clinical Laboratory, Qilu Hospital, Shandong University, 107 Wenhua West Road, Jinan, Shandong 250012, People's Republic of China.
Int J Colorectal Dis. 2013 May;28(5):697-703. doi: 10.1007/s00384-013-1674-0. Epub 2013 Mar 10.
Accumulating evidences indicate that dysregulated microRNAs (miRNA) are involved in cancer tumorigenesis and progression. In the present study, we evaluated the expression of miR-182 in colorectal cancer and adjacent noncancerous tissues and explored its associations with clinicopathological characteristics and prognosis.
Quantitative real-time PCR was used to analyze the expression of miR-182 in 148 pairs of colorectal cancer and adjacent noncancerous tissues. The relationship between miR-182 expression and clinicopathological characteristics in colorectal cancer tissues was estimated using Mann-Whitney U test or Kruskal-Wallis test, as appropriate. We calculated the survival curves and prognostic values of each variable by the Kaplan-Meier method and Cox proportional hazards regression analysis, respectively.
The expression of miR-182 was found up-regulated in colorectal cancer tissues compared with adjacent noncancerous tissues (p < 0.001), and its up-regulation was significantly correlated with large tumor size (p = 0.016), positive regional lymph node metastasis (p = 0.008), and advanced tumor-node-metastasis stage (p = 0.020). Furthermore, Kaplan-Meier analysis demonstrated that high miR-182 expression predicted poor survival (p = 0.001), and Cox proportional hazards risk analysis indicated that miR-182 was an independent prognostic factor for colorectal cancer.
MiR-182 was up-regulated in colorectal cancer tissues and correlated with adverse clinical characteristics and poor prognosis, indicating that miR-182 might be involved in colorectal cancer progression and could be used as a potential prognostic biomarker and therapeutic target in the management of colorectal cancer.
越来越多的证据表明，失调的 microRNAs（miRNA）参与了癌症的发生和发展。本研究评估了 miR-182 在结直肠癌及相邻非癌组织中的表达，并探讨了其与临床病理特征和预后的关系。
采用实时定量 PCR 分析 148 对结直肠癌及相邻非癌组织中 miR-182 的表达。采用 Mann-Whitney U 检验或 Kruskal-Wallis 检验，评估 miR-182 表达与结直肠癌组织临床病理特征的关系。采用 Kaplan-Meier 法和 Cox 比例风险回归分析分别计算各变量的生存曲线和预后价值。
miR-182 在结直肠癌组织中的表达高于相邻非癌组织（p<0.001），且其上调与肿瘤较大（p=0.016）、区域淋巴结转移阳性（p=0.008）和肿瘤-淋巴结-转移分期较晚（p=0.020）显著相关。Kaplan-Meier 分析表明，高 miR-182 表达预示着不良的生存（p=0.001），Cox 比例风险回归分析表明，miR-182 是结直肠癌的独立预后因素。
miR-182 在结直肠癌组织中上调，与不良的临床特征和不良预后相关，表明 miR-182 可能参与了结直肠癌的进展，可作为结直肠癌管理中潜在的预后生物标志物和治疗靶点。
